AI-Native vs. AI-Wrapped: Investing in True Health AI Value

The proliferation of artificial intelligence in healthcare has created a critical challenge for health plan executives and HR leaders: distinguishing between genuinely transformative AI-native solutions and those merely “AI-wrapped.” The former offers clinical rigor and verifiable outcomes, while the latter often amounts to little more than marketing gloss on conventional services. Understanding this distinction is paramount for procurement teams aiming to invest in solutions that deliver real value, improve patient outcomes, and withstand regulatory scrutiny.

The Definitional Chasm: AI-Native vs. AI-Wrapped

At its core, an AI-native health company builds its foundational product, data pipelines, and business model around AI from inception. This means the AI is not an add-on or a feature but the central architecture driving clinical utility. These companies are characterized by their training on real patient outcomes data, operation within defined clinical guardrails, and published evidence of efficacy. Conversely, AI-wrapped solutions often apply a veneer of AI to existing services, using algorithms for personalization or efficiency gains without the deep integration into clinical decision-making or the rigorous validation that defines true AI-nativity. Consider the spectrum of AI integration across various health vendors. Companies like HeartFlow exemplify an AI-native approach. Their technology, which creates a 3D model of coronary arteries from CT scans to assess blood flow, is fundamentally built on AI analysis of complex imaging data, directly informing clinical decisions and backed by extensive evidence. This contrasts sharply with many digital health apps that might use AI for personalized coaching or content delivery, such as Noom, Hims & Hers, BetterHelp, Teladoc Health, or Calm. While these companies leverage AI to enhance user experience or streamline operations, their core offerings are often digital interfaces to existing health services or content libraries, where AI plays a supportive, rather than a foundational, clinical role. The AI in these instances is typically “AI-wrapped,” improving engagement or access but not fundamentally altering the diagnostic or therapeutic pathway in a deeply validated, clinical sense. Eminent figures in digital health and AI, such as Eric Topol, have consistently emphasized the need for rigorous evidence and clinical validation in AI applications. Similarly, Ziad Obermeyer’s work frequently highlights the importance of real-world data and robust methodologies to ensure AI algorithms are not only effective but also equitable and safe. These perspectives underscore the critical difference between AI as a clinical engine and AI as a mere optimization layer. The relationship here is clear: AI-wrapped solutions are characterized by marketing claims that often lack a robust clinical AI architecture, whereas AI-native solutions are built on proprietary data, operate within clear guardrails, and provide published evidence of efficacy. Procurement teams must develop the discernment to identify this fundamental difference.

Regulatory and Ethical Imperatives: Guardrails for Genuine AI

The regulatory landscape further clarifies the distinction. The FDA’s Software as a Medical Device (SaMD) Framework provides a crucial lens through which to evaluate AI health solutions. AI-native companies, especially those whose algorithms directly impact diagnosis or treatment decisions, often fall under this framework, necessitating rigorous validation, clinical trials, and post-market surveillance. HeartFlow, for example, has navigated this path, demonstrating its clinical utility through extensive research. This regulatory pathway ensures that the AI is not just “smart” but clinically safe and effective. The FDA has also issued updated guidance for AI/ML-enabled medical devices in 2026, including finalization of Predetermined Change Control Plans (PCCPs) and updated guidance on Clinical Decision Support Software. In contrast, many AI-wrapped applications, particularly those focused on wellness, coaching, or general information, may not be classified as SaMD. While this can offer a faster path to market, it also means they operate with less stringent clinical oversight. The Federal Trade Commission (FTC) Act Section 5, which prohibits unfair or deceptive acts or practices in commerce, becomes particularly relevant here. Companies making unsubstantiated claims about AI efficacy, whether explicit or implied, risk FTC scrutiny. Rock Health, in its analyses of digital health funding and innovation, consistently points to the need for greater transparency and evidence in the burgeoning AI health sector. The FDA’s Center for Devices and Radiological Health (CDRH) further reinforces the importance of clinical evidence for AI/ML-enabled medical devices, emphasizing the need for defined clinical guardrails and demonstrable impact on patient outcomes. Commure, an AI-native enterprise healthcare platform focused on infrastructure and data interoperability, represents another facet where AI’s role can be either foundational or supplementary. While its AI tools often streamline administrative tasks or data presentation, fitting an “AI-wrapped” description for those specific functions, Commure positions its platform as AI-native, with AI deeply integrated into its core architecture to connect clinical, operational, and financial workflows. This nuance highlights that even within enterprise solutions, the depth of AI integration and clinical validation is key.

The Imperative for Informed Evaluation

For health plan executives and employers, the implications of this distinction are profound. Investing in AI-native platforms means aligning with solutions that have demonstrably improved patient outcomes, reduced costs through precision, and are built to withstand the scrutiny of clinical effectiveness and regulatory bodies. These are the solutions that can genuinely move the needle on population health and care delivery. Conversely, adopting AI-wrapped tools without understanding their limitations can lead to misallocation of resources, unmet expectations, and potential liabilities if marketing claims outstrip clinical reality. When evaluating vendors, procurement teams must go beyond buzzwords. They must demand clarity on the data used for training, the clinical guardrails in place to ensure safety and efficacy, and the published evidence supporting the AI’s impact on real patient outcomes. This rigorous approach, championed by experts like Eric Topol and Ziad Obermeyer, is not just good practice; it is essential for responsible innovation in healthcare. The future of healthcare AI hinges on our collective ability to discern genuine clinical intelligence from mere technological embellishment. FDA guidance on AI/ML in medical devices FTC guidance on health claims Rock Health reports on digital health evidence